Mesenchymal stem cells in drug/gene delivery: Implications for cell therapy

Therapeutic Delivery

Volumn 3, Issue 8, 2012, Pages 997-1004

  Greco, Steven J ^a   Rameshwar, Pranela ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CXCR4; CYTOSINE DEAMINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPHRIN RECEPTOR A2; ERYTHROPOIETIN; GAMMA INTERFERON; GLUCAGON LIKE PEPTIDE 1; INTERLEUKIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1 INHIBITOR; RINDOPEPIMUT; SCATTER FACTOR; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; SURVIVIN; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TYROSINE 3 MONOOXYGENASE; URACIL PHOSPHORIBOSYLTRANSFERASE; VASCULOTROPIN;

ALLOTRANSPLANTATION; ALZHEIMER DISEASE; ANTIGEN PRESENTING CELL; ARTICLE; CARCINOGENICITY; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL HOMING; COLON CANCER; DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; GENE DELIVERY SYSTEM; GLIOMA; HEART DISEASE; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MESENCHYMAL STEM CELL; PANCREAS CANCER; PARKINSON DISEASE; PATIENT SAFETY; PRIORITY JOURNAL; PROSTATE CANCER; STEM CELL TRANSPLANTATION; STROKE; TREATMENT INDICATION;

EID: 84865492634     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.69     Document Type: Article

References (63)

1. Meijer GJ, de Bruijn JD, Koole R, van Blitterswijk CA. Cell based bone tissue engineering in jaw defects. Biomaterials 29(21), 3053-3061 (2008).
2. Davatchi F, Abdollahi BS, Mohyeddin M, Shahram F, Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int. J. Rheum. Dis. 14(2), 211-215 (2011).
3. Orozco L, Soler R, Morera C, Alberca M, Sanchez A, Garcia-Sancho J. Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study. Transplantation 92(7), 822-828 (2011).
4. Wakitani S, Okabe T, Horibe S et al. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J. Tissue Eng. Regen. Med. 5(2), 146-150 (2011).
5. Greco SJ, Zhou C, Ye JH, Rameshwar P. An interdisciplinary approach and characterization of neuronal cells transdifferentiated from human mesenchymal stem cells. Stem Cells Dev. 16(5), 811-826 (2007). (Pubitemid 350125224)
6. Franquesa M, Herrero E, Torras J et al. Mesenchymal stem cell therapy prevents IFTA in a rat kidney allograft model. Stem Cells Dev. (2012) (Epub ahead of print).
7. Sakai Y, Kaneko S. Mesenchymal stem cell therapy on murine model of nonalcoholic steatohepatitis. Methods Mol. Biol. 826, 217-223 (2012).
8. Nourissat G, Diop A, Maurel N et al. Mesenchymal stem cell therapy regenerates the native bone-tendon junction after surgical repair in a degenerative rat model. PLoS ONE 5(8), e12248 (2010).
9. Lee KB, Hui JH, Song IC, Ardany L, Lee EH. Injectable mesenchymal stem cell therapy for large cartilage defects - a porcine model. Stem Cells 25(11), 2964-2971 (2007). (Pubitemid 350127882)
10. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J. Exp. Med. 184(3), 1101-1109 (1996). (Pubitemid 26313567)
11. Schantz JT, Chim H, Whiteman M. Cell guidance in tissue engineering: SDF-1 mediates site-directed homing of mesenchymal stem cells within three-dimensional polycaprolactone scaffolds. Tissue Eng. 13(11), 2615-2624 (2007). (Pubitemid 350076752)
12. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419), 1439-1441 (2004). (Pubitemid 38586721)
13. Lazarus HM, Koc ON, Devine SM et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol. Blood Marrow Transplant. 11(5), 389-398 (2005). (Pubitemid 40542932)
14. Ringden O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81(10), 1390-1397 (2006). (Pubitemid 43847148)
15. Perez-Simon JA, Lopez-Villar O, Andreu EJ et al. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a Phase I/II clinical trial. Haematologica 96(7), 1072-1076 (2011).
16. Arima N, Nakamura F, Fukunaga A et al. Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study. Cytotherapy 12(2), 265-268 (2010).
17. Connick P, Kolappan M, Patani R et al. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials 12, 62 (2011).
18. Yamout B, Hourani R, Salti H et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J. Neuroimmunol. 227(1-2), 185-189 (2010).
19. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J. Immunol. 171(7), 3426-3434 (2003). One of the pioneering studies to define the immune properties of mesenchymal stem cells (MSCs). (Pubitemid 37254543)
20. Chan JL, Tang KC, Patel AP et al. Antigenpresenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 107(12), 4817-4824 (2006). (Pubitemid 43882633)
21. Ra JC, Shin IS, Kim SH et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev. 20(8), 1297-1308 (2011). Demonstrates the safety and tolerability profile of human MSCs in vivo.
22. Wang Y, Huso DL, Harrington J et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy 7(6), 509-519 (2005). (Pubitemid 43078081)
23. Yamaoka E, Hiyama E, Sotomaru Y et al. Neoplastic transformation by TERT in FGF-2-expanded human mesenchymal stem cells. Int. J. Oncol. 39(1), 5-11 (2011).
24. Balyasnikova IV, Ferguson SD, Sengupta S, Han Y, Lesniak MS. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma. PLoS ONE 5(3), e9750 (2010).
25. Choi SA, Hwang SK, Wang KC et al. Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma. Neuro. Oncol. 13(1), 61-69 (2011). Study exemplifying the use of engineered MSCs as cytotoxic agents.
26. Kim SM, Oh JH, Park SA et al. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem Cells 28(12), 2217-2228 (2010).
27. Nakamura K, Ito Y, Kawano Y et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 11(14), 1155-1164 (2004). (Pubitemid 39117311)
28. Sun XL, Xu ZM, Ke YQ et al. Molecular targeting of malignant glioma cells with an EphA2-specific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells. Cancer Lett. 312(2), 168-177 (2011).
29. Hu W, Wang J, He X et al. Human umbilical blood mononuclear cell-derived mesenchymal stem cells serve as interleukin-21 gene delivery vehicles for epithelial ovarian cancer therapy in nude mice. Biotechnol. Appl. Biochem. 58(6), 397-404 (2011).
30. Park SA, Ryu CH, Kim SM et al. CXCR4-transfected human umbilical cord bloodderived mesenchymal stem cells exhibit enhanced migratory capacity toward gliomas. Int. J. Oncol. 38(1), 97-103 (2011).
31. Pessina A, Bonomi A, Cocce V et al. Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS ONE 6(12), e28321 (2011).
32. Hsiao WC, Sung SY, Liao CH, Wu HC, Hsieh CL. Vitamin D (3)-Inducible Mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth. Mol. Pharm. 9(5), 1396-408 (2012).
33. Choi SA, Lee JY, Wang KC et al. Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas. Eur. J. Cancer 48(1), 129-137 (2012). Study exemplifies how MSCs engineered with specialized enzymes could be utilized as a vehicle for targeted delivery of a toxic drug to a region of interest following peripheral administration of a prodrug.
34. Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner C. Adipose tissuederived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res. 67(13), 6304-6313 (2007). (Pubitemid 47037513)
35. Song C, Xiang J, Tang J et al. Thymidine kinase gene modified bone marrow mesenchymal stem cells as vehicles for antitumor therapy. Hum. Gene Ther. 22(4), 439-449 (2011).
36. Cavarretta IT, Altanerova V, Matuskova M, Kucerova L, Culig Z, Altaner C. Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol. Ther. 18(1), 223-231 (2010).
37. Kidd S, Caldwell L, Dietrich M et al. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 12(5), 615-625 (2010).
38. Mohr A, Lyons M, Deedigan L et al. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J. Cell. Mol. Med. 12(6 B), 2628-2643 (2008).
39. Li X, Lu Y, Huang W et al. In vitro effect of adenovirus-mediated human gamma interferon gene transfer into human mesenchymal stem cells for chronic myelogenous leukemia. Hematol. Oncol. 24(3), 151-158 (2006). (Pubitemid 44483909)
40. Kurozumi K, Nakamura K, Tamiya T et al. BDNF gene-modified mesenchymal stem cells promote functional recovery and reduce infarct size in the rat middle cerebral artery occlusion model. Mol. Ther. 9(2), 189-197 (2004). (Pubitemid 38256545)
41. Somoza R, Juri C, Baes M, Wyneken U, Rubio FJ. Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson's disease. Biol. Blood Marrow Transplant. 16(11), 1530-1540 (2010).
42. Cho GW, Koh SH, Kim MH et al. The neuroprotective effect of erythropoietintransduced human mesenchymal stromal cells in an animal model of ischemic stroke. Brain Res. 1353, 1-13 (2010).
43. Liu N, Zhang Y, Fan L et al. Effects of transplantation with bone marrow-derived mesenchymal stem cells modified by survivin on experimental stroke in rats. J. Transl. Med. 9, 105 (2011).
44. Toyama K, Honmou O, Harada K et al. Therapeutic benefits of angiogenetic gene-modified human mesenchymal stem cells after cerebral ischemia. Exp. Neurol. 216(1), 47-55 (2009).
45. Xiong N, Zhang Z, Huang J et al. VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson's disease. Gene Ther. 18(4), 394-402 (2011).
46. Lu L, Zhao C, Liu Y et al. Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease. Brain Res. Brain Res. Protoc. 15(1), 46-51 (2005). (Pubitemid 40616871)
47. Klinge PM, Harmening K, Miller MC et al. Encapsulated native and glucagon-like peptide-1 transfected human mesenchymal stem cells in a transgenic mouse model of Alzheimer's disease. Neurosci. Lett. 497(1), 6-10 (2011).
48. Greco SJ, Rameshwar P. Enhancing effect of IL-1alpha on neurogenesis from adult human mesenchymal stem cells: implication for inflammatory mediators in regenerative medicine. J. Immunol. 179(5), 3342-3350 (2007).
49. Grigoriadis N, Lourbopoulos A, Lagoudaki R et al. Variable behavior and complications of autologous bone marrow mesenchymal stem cells transplanted in experimental autoimmune encephalomyelitis. Exp. Neurol. 230(1), 78-89 (2011).
50. Snyder EY. The risk of putting something where it does not belong: mesenchymal stem cells produce masses in the brain. Exp. Neurol. 230(1), 75-77 (2011).
51. Madonna R, De Caterina R. Stem cells and growth factor delivery systems for cardiovascular disease. J. Biotechnol. 154(4), 291-297 (2011).
52. Tang J, Wang J, Yang J et al. Mesenchymal stem cells over-expressing SDF-1 promote angiogenesis and improve heart function in experimental myocardial infarction in rats. Eur. J. Cardiothorac. Surg. 36(4), 644-650 (2009).
53. Haider H, Jiang S, Idris NM, Ashraf M. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ. Res. 103(11), 1300-1308 (2008).
54. Huang J, Zhang Z, Guo J et al. Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ. Res. 106(11), 1753-1762 (2010). Study demonstrates how gene therapy can be utilized to promote the regenerative capabilities of transplanted MSCs.
55. Duan HF, Wu CT, Wu DL et al. Treatment of myocardial ischemia with bone marrowderived mesenchymal stem cells overexpressing hepatocyte growth factor. Mol. Ther. 8(3), 467-474 (2003).
56. Matsumoto R, Omura T, Yoshiyama M et al. Vascular endothelial growth factorexpressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 25(6), 1168-1173 (2005). (Pubitemid 40776604)
57. Sun L, Cui M, Wang Z et al. Mesenchymal stem cells modified with angiopoietin-1 improve remodeling in a rat model of acute myocardial infarction. Biochem. Biophys. Res. Commun. 357(3), 779-784 (2007). (Pubitemid 46653847)
58. Kuraitis D, Hou C, Zhang Y et al. Ex vivo generation of a highly potent population of circulating angiogenic cells using a collagen matrix. J. Mol. Cell. Cardiol. 51(2), 187-197 (2011).
59. Godier-Furnemont AF, Martens TP, Koeckert MS et al. Composite scaffold provides a cell delivery platform for cardiovascular repair. Proc. Natl Acad. Sci. USA 108(19), 7974-7979 (2011).
60. Perez CM, Panitch A, Chmielewski J. A collagen peptide-based physical hydrogel for cell encapsulation. Macromol. Biosci. 11(10), 1426-1431 (2011).
61. Zhou H, Xu HH. The fast release of stem cells from alginate-fibrin microbeads in injectable scaffolds for bone tissue engineering. Biomaterials 32(30), 7503-7513 (2011).
62. Saito S, Nakayama T, Hashimoto N et al. Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycin-induced lung damage. Am. J. Pathol. 179(3), 1088-1094 (2011).
63. Kanki-Horimoto S, Horimoto H, Mieno S et al. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation 114(Suppl. 1), I181-I185 (2006). (Pubitemid 44297148)